{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"67.2","upperLimit":"87.1","value":"78.8"},{"groupId":"OG001","lowerLimit":"68.5","upperLimit":"88.1","value":"76.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"68"}],"units":"Participants"}],"description":"The Kaplan-Meier method will be used to estimate the 2-year EFS for each of the treatment regimens.","dispersionType":"95% Confidence Interval","groups":[{"description":"COURSE A (CYCLES 1, 3, AND 5): Patients receive brentuximab vedotin IV over 30 minutes on day 1, dexamethasone PO BID or IV on days 1-5, ifosfamide IV over 60 minutes on days 1-5, methotrexate IV over 3 hours on day 1, cytarabine IV over 1-30 minutes every 12 hours for 4 doses on days 4 and 5, and etoposide IV over 2 hours on days 4 and 5.\n\nCOURSE B (CYCLES 2, 4, AND 6): Patients receive brentuximab vedotin, dexamethasone, and methotrexate as in Arm BV, Course A. Patients also receive cyclophosphamide IV over 15-30 minutes on days 1-5 and doxorubicin hydrochloride IV over 1-15 minutes on days 4 and 5.\n\nBrentuximab Vedotin: Given IV\n\nCyclophosphamide: Given IV\n\nCytarabine: Given IT and IV\n\nDexamethasone: Given PO or IV\n\nDoxorubicin Hydrochloride: Given IV\n\nEtoposide: Given IV\n\nIfosfamide: Given IV\n\nMethotrexate: Given IT and IV","id":"OG000","title":"Arm BV (Brentuximab Vedotin, Combination Chemotherapy)"},{"description":"COURSE A (CYCLES 1, 3, AND 5): Patients receive crizotinib PO BID on days 1-21 and dexamethasone, ifosfamide, methotrexate, cytarabine, and etoposide as in Arm BV, Course A.\n\nCOURSE B (CYCLES 2, 4, AND 6): Patients receive crizotinib as in Arm CZ, Course A and dexamethasone, cyclophosphamide, methotrexate, and doxorubicin hydrochloride as in Arm BV, Course B.\n\nCrizotinib: Given PO\n\nCyclophosphamide: Given IV\n\nCytarabine: Given IT and IV\n\nDexamethasone: Given PO or IV\n\nDoxorubicin Hydrochloride: Given IV\n\nEtoposide: Given IV\n\nIfosfamide: Given IV\n\nMethotrexate: Given IT and IV","id":"OG001","title":"Arm CZ (Crizotinib, Combination Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"1 Arm CZ patient who did not start treatment is excluded from analyses of EFS.","reportingStatus":"POSTED","timeFrame":"Time from study entry until progressive disease, relapse, or death, assessed up to 2 years","title":"Event Free Survival (EFS)","type":"PRIMARY","unitOfMeasure":"Percentage of patients"}